CRDF Cardiff Oncology, Inc. Insider Trading

CEO Mani Mohindru purchases 24,703 shares of CRDF at $1.21 amid -73.5% decline from 52-week high

Mani Mohindru, Chief Executive Officer, acquired 24,703 shares at $1.21 on 2026-06-18, increasing his holdings from 0 to 24,703 shares. The purchase occurs after the stock has declined -73.5% from its 52-week high of $4.56, and the company has contracted by -13.2% in annual revenue while posting a net loss of $-12.3M in its most recent fiscal year. This represents the CEO's initial stock position. The transaction occurs in a context of significant stock price weakness and ongoing operational losses, but the limited position size (24.7K shares out of an $82.7M market cap) and recent price momentum (down -31.2% in 30 days and -32.8% in 90 days) provide limited basis for inferring conviction at this level.

Director Gary W Pace buys 30,000 shares of CRDF at $1.22; stock down 73.5% from 52-week high, now at $1.21

Gary W Pace, a Director of Cardiff Oncology, purchased 30,000 shares at $1.22 on 2026-06-18, bringing his holdings to 1.36M shares. The purchase occurs at a substantial discount to the 52-week high, with the stock trading at -73.5% from that peak and -31.2% over the past 30 days. His prior purchases at CRDF show mixed results: two early 2025 buys declined 14.3% over 30 days, while a December 2024 purchase rose 38.8% in the same window, and a December 2023 purchase ultimately gained 277.4% over 90 days. The company faces headwinds—annual revenue declined 13.2% and it is unprofitable with a $-12.3M net loss on $41.0K quarterly revenue. While Pace's cross-ticker track record shows a 66.67% 90-day win rate on buys and a 90d average return of +70.7%, his same-ticker history at CRDF is less consistent, with 3 of 5 prior buys achieving positive 90-day returns.

Director Gary Pace purchases 290,000 shares of CRDF at $2.45 for $710,500 total; stake grows 27.5% post-transaction to 1,345,676 shares.

Director Gary W. Pace executed 2 separate purchases totaling 290,000 shares for $710,500.00 on 2025-07-30, increasing his holdings from 1,055,676 shares to 1,345,676 shares—a 27.5% increase. His four prior buys at CRDF achieved a 100% win rate at the 90-day mark (ranging from +37.7% to +277.4%), and his cross-ticker buy track record shows an average 90d return of +109.1% with a 100.00% win rate. This transaction occurs as the stock trades at $2.37, down 55.7% from its 52-week high of $5.35 and down 32.5% over the last 30 days, though Cardiff Oncology reported revenue of $121,000.00 in its latest quarter and remains unprofitable with a net income of $-13.9M. The scale of the acquisition—nearly 290.0K shares—and the historical accuracy of Pace's prior timing decisions provide material context for investors monitoring director-level capital deployment during a period of significant price decline.

CFO James E. Levine purchases 7,716 shares across 3 transactions at $4.76 blended average; cluster buy with 2 other insiders in past 14 days.

CFO James E. Levine executed 3 separate purchases totaling 7,716 shares for $36,725.50, increasing his holdings by 12.9% from 60,000 to 67,716 shares over three consecutive trading days (Dec 16-18, 2024). The timing spans a period when the stock moved from $3.83 to $5.42, and the company is currently trading at $4.49, down 24.0% from its 52-week high of $5.91 but up 74.0% over the past 30 days and 77.5% over 90 days. Cardiff Oncology remains unprofitable with a net income of $-11.9M despite 26.4% annual revenue growth, and concurrent purchases by 2 other insiders within the past 14 days indicate a cluster buy pattern. This coordinated insider accumulation at a stage when the stock has recently rebounded substantially merits attention to understand whether insiders perceive fundamental improvement or valuation opportunity.

Director Renee P. Tannenbaum doubles stake to 20,000 shares in unprofitable CRDF; cluster buy pattern amid +56.2% 30-day rally

Director Renee P. Tannenbaum purchased 10,000 shares at $3.42 on 2024-12-12, doubling her holdings from 10,000 to 20,000 shares. This transaction is part of a cluster buy pattern—2 other insiders also purchased shares within the past 14 days. The purchase occurred after Cardiff Oncology's stock rallied +56.2% over 30 days and +58.7% over 90 days from deeper levels, though the stock remains -31.8% from its 52-week high of $5.91. While the company achieved +26.4% annual revenue growth, it posted a net loss of $-11.9M in its most recent full fiscal year with quarterly revenue of only $165.0K, indicating an early-stage or transitional biotech profile. The convergence of multiple director purchases alongside significant recent price momentum and persistent unprofitability warrants scrutiny of whether this activity reflects fundamentals or opportunistic positioning in a volatile stock.

Director PACE GARY W purchases 361.6K shares at $2.60 for $940.2K, raising stake to 1.06M shares (+51.8%)

Director Gary W. Pace completed 2 separate purchases totaling 361,615 shares for $940,199.00 at $2.60 per share on 2024-12-11, expanding his holdings by 51.8% to 1,059,376 shares post-transaction. This represents a substantial accumulation by a senior company insider at a price point 44.7% below the stock's 52-week high. Notably, Pace's prior 2 trades at Cardiff Oncology were both well-timed, with 90-day returns of +277.4% and +83.7%, establishing a pattern of accumulation preceding significant appreciation at this ticker. The company remains unprofitable ($-11.9M net income in the latest full year) with minimal quarterly revenue ($165.0K), though it posted 26.4% annual revenue growth, suggesting the stock may remain volatile until the business achieves cash-flow sustainability.